Evidence map›Paper›PMID 41785742›Full record

ArticleBreast (Edinburgh, Scotland)2026

Impact of screening on late-stage breast cancer in the Netherlands: a population-based cohort study (2007-2016).

Yixuan Lin, Grigory Sidorenkov, Jing Wang, Marcel J W Greuter, Nehmat Houssami, Monique D Dorrius, Sabine Siesling, Linda de Munck, Geertruida H de Bock

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yixuan LinDepartment of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Grigory SidorenkovDepartment of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Department of Radiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Jing WangDepartment of Epidemiology and Health Statistics, School of Public Health, Hangzhou Medical College, Hangzhou, China.
Marcel J W GreuterDepartment of Radiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Nehmat HoussamiThe Daffodil Centre, The University of Sydney, a Partnership with Cancer Council NSW, Sydney, NSW, Australia.
Monique D DorriusDepartment of Radiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Sabine SieslingDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands; Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands.
Linda de MunckDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
Geertruida H de BockDepartment of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: g.h.de.bock@umcg.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer (BC) screening can detect BC early to reduce mortality. This study evaluated the impact of BC screening on the incidence of late-stage BC in a population-based setting in the Netherlands.

methodsAll Dutch women aged 50-74 years diagnosed with invasive BC or ductal carcinoma in situ (DCIS) between 2007 and 2016 (n = 108,253) were included from the Netherlands Cancer Registry. BC was classified as screen-related if diagnosed within 24 months the last screening attendance, and as screen-detected if diagnosed within 12 months after positive screening result. Late-stage BC was defined in two ways: advanced BC, including TNM stages T3, T4, or N2, N3, or M1, and metastatic BC, defined as M1 disease. Multivariable logistic regression adjusted for age and socioeconomical status was used to assess associations between screen-related and screen-detected BC and late-stage BC. Analyses were done overall and stratified by HR/HER2-defined subtypes.

findingsBC incidence increased between 2007 and 2013 and decreased slightly thereafter. Advanced BC incidence decreased between 2007 and 2016, while metastatic BC rates remained stable. Non-screen-related BCs were significantly more likely to be present as late disease compared with screen-related (advanced BC: aOR = 3.24, 95%CI = 3.12-3.37; metastatic BC: aOR = 6.40, 95%CI = 5.98-6.85). Similarly, non-screen-detected BCs had substantial higher odds of being late than screen-detected BCs (advanced BC: aOR = 5.54, 95%CI = 5.31-5.78; metastatic BC: aOR = 12.66, 95% CI = 11.41-14.05) than screen-detected BCs. These associations were observed across all HR/HER2-defined subtypes.

interpretationPopulation-based screening is strongly associated with earlier-stage breast cancer at diagnosis, consistently across all immunohistochemistry subtypes.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingEarly Detection of CancerAgedCohort StudiesFemaleHumansIncidenceMammographyMass ScreeningMiddle AgedNeoplasm StagingNetherlandsRegistriesBreast neoplasmsCancer screeningIncidence

Identifiers

PMID41785742
PMCPMC12972954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.